Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Maternal Non-Anemic Iron Deficiency in Early Pregnancy and Infant Neurodevelopment: A Critical Appraisal.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026

Same author

The association of thrombocytopenia with haematological malignancy.

British journal of haematology·2026

Same author

Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?

Therapeutic advances in hematology·2026

Same author

National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Same author

Assessing preoperative bleeding risk using international normalized ratio and activated partial thromboplastin time: a systematic review.

Journal of thrombosis and haemostasis : JTH·2026

Same author

Hemoglobin Concentration in Early Pregnancy and Severe Neonatal Morbidity and Mortality : A Population-Based Cohort Study.

Annals of internal medicine·2026

Same journal

Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.

Research and practice in thrombosis and haemostasis·2026

Same journal

Thromboembolic ischemic stroke induces neutrophil recruitment and matrix metalloproteinase-9 release to enhance ischemic brain injury.

Research and practice in thrombosis and haemostasis·2026

Same journal

Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding.

Research and practice in thrombosis and haemostasis·2026

Same journal

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2026

Same journal

Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis.

Research and practice in thrombosis and haemostasis·2026

Same journal

Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.

Research and practice in thrombosis and haemostasis·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 30, 2026

$Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy$

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

Malignant benign hematology.

Michelle Sholzberg¹

¹Departments of Medicine and Laboratory Medicine and Pathobiology St. Michael's Hospital Li Ka Shing Knowledge Institute University of Toronto Toronto Ontario Canada.

Research and Practice in Thrombosis and Haemostasis

|January 19, 2019

Summary

This summary is machine-generated.

The term "benign" is misleading for severe non-cancerous blood disorders. Reconsidering this label is crucial for improving patient care and research in hematology.

Keywords:

hematology hemophilia A idiopathic thrombocytopenic purpura thrombophilia thrombotic microangiopathy

More Related Videos

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

Three Dimensional Cultures: A Tool To Study Normal Acinar Architecture vs. Malignant Transformation Of Breast Cells

Three Dimensional Cultures: A Tool To Study Normal Acinar Architecture vs. Malignant Transformation Of Breast Cells

Published on: April 25, 2014

Related Experiment Videos

Last Updated: Jan 30, 2026

$Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy$

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

Three Dimensional Cultures: A Tool To Study Normal Acinar Architecture vs. Malignant Transformation Of Breast Cells

Three Dimensional Cultures: A Tool To Study Normal Acinar Architecture vs. Malignant Transformation Of Breast Cells

Published on: April 25, 2014

Area of Science:

Hematology
Internal Medicine

Background:

Life-threatening non-cancerous blood disorders, such as catastrophic antiphospholipid antibody syndrome, acquired hemophilia, and severe immune thrombocytopenia, are challenging to manage.
These conditions often lack robust evidence for treatment strategies and are difficult to treat effectively.
The term "benign" inaccurately minimizes the severity and impact of these hematologic conditions.

Purpose of the Study:

To challenge the use of the term "benign" in hematology for non-malignant, yet life-threatening, blood disorders.
To highlight the discrepancies in prioritization and care that arise from labeling these severe conditions as "benign."
To advocate for a re-evaluation of terminology to better reflect the clinical reality and urgency of these diseases.

Main Methods:

Review of clinical challenges and evidence gaps in managing severe non-malignant hematologic disorders.
Analysis of the impact of the term "benign" on healthcare prioritization and patient perception.
Discussion of the need for enhanced international collaboration, research infrastructure, and clinical training.

Main Results:

The label "benign" is a misnomer for severe non-cancerous blood disorders, leading to underestimation of their impact.
Existing management strategies are often hampered by a lack of high-quality, unbiased clinical trial data.
There are significant knowledge and care gaps that require greater international collaboration and resources.

Conclusions:

The term "benign hematology" is inappropriate and potentially harmful, affecting prioritization and resource allocation.
Addressing critical knowledge and care gaps necessitates increased international collaboration, research infrastructure, and specialized training.
It is time to reconsider and potentially abandon the term "benign" in the context of severe non-malignant blood disorders to improve patient outcomes.